Compare ACADIA Pharmaceuticals Inc. (ACAD) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs General Motors Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.54 (market cap $5.07B), while General Motors Company trades at $87.08 (market cap $78.40B). The key difference: General Motors Company is far larger — about 15.5× ACADIA Pharmaceuticals Inc.'s market cap, and General Motors Company pays a 0.81% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GM | |
|---|---|---|
Market Cap | $5.07B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $90.30 |
52-Week Low | $20.06 | $54.16 |
Enterprise Value | $4.19B | $181.38B |
Dividend Yield | — | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
General Motors (GM) trades at $87.74, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company has demonstrated consistent earnings outperformance, beating estimates in the last three quarters. Recent strategic moves include a $4.5 billion parts supply deal and extending its China joint venture for 20 years. Valuation metrics show attractive P/S and P/B ratios, though profitability margins remain thin with net income margin at 1.05%.
GM presents a compelling investment case with analyst consensus pointing to 24% upside to the $108.82 price target. Strong cash flow generation and strategic partnerships support growth prospects, but investors face risks from declining profit margins, rising debt levels, and automotive industry cyclicality. The stock's current technical positioning near key support levels suggests potential for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
